A5001586818- BRCA gene mutations in cancer
- Chronic Lymphocytic Leukemia Research
- Acute Myeloid Leukemia Research
- Biochemical and Molecular Research
- Click Chemistry and Applications
- Occupational and environmental lung diseases
- Cell Adhesion Molecules Research
- Cytokine Signaling Pathways and Interactions
- Radiopharmaceutical Chemistry and Applications
- Nutrition, Genetics, and Disease
- Flame retardant materials and properties
Hospital Privado
2023-2024
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematological malignancies characterized by ineffective hematopoiesis, resulting in cytopenias, morphologic dysplasia hematopoietic lineages, and variable risk progression to acute myeloid leukemia. Significant advances the understanding MDS have been made recent years, largely due implementation molecular tools. Latin America is highly diverse region, both ethnically racially, often faces resource limitations that challenge broad...
The Molecular International Prognostic Scoring System (IPSS-M) has improved the prediction of clinical outcomes for myelodysplastic syndromes (MDS). Artificial Intelligence MDS (AIPSS-MDS), based on classical parameters, outperformed IPSS, revised version (IPSS-R). For first time, we validated IPSS-M and other molecular prognostic models compared them with established IPSS-R AIPSS-MDS using data from South American patients.
e22534 Background: The use of NGS has made it easier and more cost-effective to analyze genes associated with hereditary cancer predisposition syndromes. Germline alterations in breast (BC) have an estimated prevalence 10.7% Pathogenic Variant or Likely (P/LP), up 8.0% BRCA1/2 2.7% CHEK2, ATM PALB2 genes; they increase the risk 2 5 times. To date, two studies P/LP non-BRCA1/2 been conducted Argentina frequencies 4.5 4.7% patients personal and/or family history BC. Methods: We report...